Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Keymed Biosciences Inc. (2162.HK)
Chengdu, CN
Keymed Biosciences Inc., a biotechnology firm founded in 2016 in Chengdu, China (formerly known as 2Health Biosciences, Inc.), specializes in the research and development of innovative biological treatments, primarily targeting autoimmune and oncology diseases. A cornerstone of their pipeline is CM310, their lead product candidate, which is currently being developed for the management of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). Complementing this, the company is also progressing CM326, a monoclonal antibody designed to inhibit thymic stromal lymphopoietin, for similar indications such as AD, CRSwNP, asthma, and COPD. In the realm of oncology, Keymed is developing CMG901 for solid tumors, particularly those affecting the stomach and gastroesophageal junction. Another significant candidate, CM313, is a humanized monoclonal antibody slated for the treatment of relapsed or refractory multiple myeloma, lymphoma, other blood cancers, and systemic lupus erythematosus. Their extensive portfolio further includes MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectin-associated serine protease-2; CM355, intended for relapsed or refractory non-Hodgkin's lymphoma; CM336, for multiple myeloma; CM350, for various solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.64% | +0.24% | -18.20% | +19.19% | -0.88% | +15.62% | +40.14% | +46.45% | -9.12% | -9.12% | -9.12% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | +1 |
| Buy | 6 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+63.0% ★ Q4'25: +693.2% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+5.6% Q4'25: +6.4% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-106.5% Q4'25: -258.5% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-83.8% Q4'25: -220.2% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-36.5% Q4'25: -117.4% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+4.6% Q4'25: +14.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.61× Q4'25: -0.47× (vs Q4'23)
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 3 EPS Ana. |
Dec 2027 5 Rev. Ana. 3 EPS Ana. |
Dec 2028 5 Rev. Ana. 4 EPS Ana. |
Dec 2029 2 Rev. Ana. 2 EPS Ana. |
Dec 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
110.27M
est: 90.14M (+22.3%)
|
100.06M
est: 120.87M (-17.2%)
|
354.10M
est: 75.95M (+366.2%)
|
428.12M
est: 203.90M (+110.0%)
|
697.77M
est: 765.73M (-8.9%)
|
2.29B
1.68B – 2.50B
+199.3% YoY
|
2.10B
1.65B – 2.43B
-8.3% YoY
|
3.01B
2.28B – 3.38B
+43.4% YoY
|
3.36B
2.54B – 3.76B
+11.4% YoY
|
3.80B
2.87B – 4.25B
+13.0% YoY
|
| EBITDA |
-3.86B
est: -49.79M (-7,653.8%)
|
-259.26M
est: -66.77M (-288.3%)
|
-269.77M
est: -67.80M (-297.9%)
|
-574.46M
est: -182.01M (-215.6%)
|
-489.36M
est: -683.52M (+28.4%)
|
-2.05B
-2.23B – -1.50B
-199.3% YoY
|
-1.88B
-2.17B – -1.47B
+8.3% YoY
|
-2.69B
-3.01B – -2.04B
-43.4% YoY
|
-3.00B
-3.36B – -2.27B
-11.4% YoY
|
-3.39B
-3.79B – -2.57B
-13.0% YoY
|
| EBIT |
-3.88B
est: -53.31M (-7,181.1%)
|
-295.38M
est: -71.49M (-313.2%)
|
-338.93M
est: -72.84M (-365.3%)
|
-626.09M
est: -195.55M (-220.2%)
|
-584.85M
est: -734.39M (+20.4%)
|
-2.20B
-2.40B – -1.62B
-199.3% YoY
|
-2.02B
-2.33B – -1.58B
+8.3% YoY
|
-2.89B
-3.24B – -2.19B
-43.4% YoY
|
-3.22B
-3.61B – -2.44B
-11.4% YoY
|
-3.64B
-4.08B – -2.76B
-13.0% YoY
|
| Net Income |
-3.90B
est: -1.16B (-234.7%)
|
-308.12M
est: -246.32M (-25.1%)
|
-359.36M
est: -691.20M (+48.0%)
|
-515.24M
est: -678.44M (+24.1%)
|
-509.11M
est: -509.75M (+0.1%)
|
565.38M
564.33M – 566.43M
+210.9% YoY
|
3.72M
1.45M – 5.99M
-99.3% YoY
|
262.48M
135.16M – 469.78M
+6,954.3% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
130.39M
est: 85.06M (+53.3%)
|
133.91M
est: 114.07M (+17.4%)
|
177.01M
est: 65.10M (+171.9%)
|
298.83M
est: 174.75M (+71.0%)
|
395.39M
est: 656.27M (-39.8%)
|
1.96B
1.44B – 2.14B
+199.3% YoY
|
1.80B
1.41B – 2.08B
-8.3% YoY
|
2.58B
1.96B – 2.89B
+43.4% YoY
|
2.88B
2.18B – 3.22B
+11.4% YoY
|
3.25B
2.46B – 3.64B
+13.0% YoY
|
| EPS |
-24.24
est: -4.45 (-445.1%)
|
-1.18
est: -1.35 (+12.7%)
|
-1.37
est: -2.64 (+48.2%)
|
-1.97
est: -2.69 (+26.8%)
|
-1.86
est: -1.83 (-1.4%)
|
2.06
2.06 – 2.07
+212.5% YoY
|
0.01
0.01 – 0.02
-99.3% YoY
|
1.38
0.49 – 1.71
+10,078.7% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bo Chen | Executive Chairman & Chief Executive Officer | 6M | — |
| Changyu Wang | Senior Vice President & Executive Director | 3M | — |
| Gang Xu | Senior Vice President & Executive Director | 3M | — |
| Pak Yu Tam | Joint Company Secretary | — | female |
| Qian Jia | Senior Vice President | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2162.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
